Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review.

Julian P T Higgins, Karla Soares-Weiser, José A López-López, Artemisia Kakourou, Katherine Chaplin, Hannah Christensen, Natasha K Martin, Jonathan A C Sterne, Arthur L Reingold

Journal: BMJ (Clinical research ed.) 2017;355():i5170

PMID: 27737834

Abstract

OBJECTIVES

 To evaluate the effects on non-specific and all cause mortality, in children under 5, of Bacillus Calmette-Guérin (BCG), diphtheria-tetanus-pertussis (DTP), and standard titre measles containing vaccines (MCV); to examine internal validity of the studies; and to examine any modifying effects of sex, age, vaccine sequence, and co-administration of vitamin A.

DESIGN

 Systematic review, including assessment of risk of bias, and meta-analyses of similar studies.

STUDY ELIGIBILITY CRITERIA

 Clinical trials, cohort studies, and case-control studies of the effects on mortality of BCG, whole cell DTP, and standard titre MCV in children under 5.

DATA SOURCES

 Searches of Medline, Embase, Global Index Medicus, and the WHO International Clinical Trials Registry Platform, supplemented by contact with experts in the field. To avoid overlap in children studied across the included articles, findings from non-overlapping birth cohorts were identified.

RESULTS

 Results from 34 birth cohorts were identified. Most evidence was from observational studies, with some from short term clinical trials. Most studies reported on all cause (rather than non-specific) mortality. Receipt of BCG vaccine was associated with a reduction in all cause mortality: the average relative risks were 0.70 (95% confidence interval 0.49 to 1.01) from five clinical trials and 0.47 (0.32 to 0.69) from nine observational studies at high risk of bias. Receipt of DTP (almost always with oral polio vaccine) was associated with a possible increase in all cause mortality on average (relative risk 1.38, 0.92 to 2.08) from 10 studies at high risk of bias; this effect seemed stronger in girls than in boys. Receipt of standard titre MCV was associated with a reduction in all cause mortality (relative risks 0.74 (0.51 to 1.07) from four clinical trials and 0.51 (0.42 to 0.63) from 18 observational studies at high risk of bias); this effect seemed stronger in girls than in boys. Seven observational studies, assessed as being at high risk of bias, have compared sequences of vaccines; results of a subset of these suggest that administering DTP with or after MCV may be associated with higher mortality than administering it before MCV.

CONCLUSIONS

 Evidence suggests that receipt of BCG and MCV reduce overall mortality by more than would be expected through their effects on the diseases they prevent, and receipt of DTP may be associated with an increase in all cause mortality. Although efforts should be made to ensure that all children are immunised on schedule with BCG, DTP, and MCV, randomised trials are needed to compare the effects of different sequences.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Address: School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK [email protected].; Cochrane, St Albans House, London SW1Y 4QX, UK.; School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK.; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.; School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Division of Epidemiology, School of Public Health, University of California, Berkeley, CA 94720-7358, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.